1. IPASS study. In: IRESSA. 2016; 3: 29. Available: http://www.iressa.com/ipass-study.html.
2. Health C for D and R. In Vitro Diagnostics—Laboratory Developed Tests. In: U.S. Food and Drug Administration (FDA). 2016; 3: 29. Available: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407296.htm.
3. Health C for D and R. In Vitro Diagnostics—Companion Diagnostics. In: U.S. Food and Drug Administration (FDA). 2016; 3: 29. Available: http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/InVitroDiagnostics/ucm407297.htm.
4. WHO | Cancer. In: WHO. 2016; 3: 29. Available: http://www.who.int/mediacentre/factsheets/fs297/en/.
5. Ontario, Ministry of Health and Long-Term Care, Medical Advisory Secretariat. Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer an evidence-based analysis Toronto, Ont.: Medical Advisory Secretariat, Ontario Ministry of Health and Long-Term Care; 2011. Available: http://www.deslibris.ca/ID/227827